XNCR Xencor Inc

8-K Current Report

Filed: March 9, 2026

Health Care

Pharmaceutical Preparations

Xencor Inc (XNCR) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 1.02: Termination of a Material Definitive Agreement

AI Filing Analysis
8-K

Item 1.02 · Termination of a Material Definitive Agreement

• Genentech terminating collaboration agreement with Xencor effective September 4, 2026 — "for convenience" clause invoked
• Sole active drug (efbalropendekin alfa, engineered cytokine-Fc fusion) already cut from Roche's pipeline in January 2025 — termination largely expected

+2 more insights

Other Xencor Inc 8-K Filings

8-K Mar 4, 2026

8-K Feb 25, 2026

Get deeper insights on Xencor Inc

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.